Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Trial Profile

Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2015

At a glance

  • Drugs Abiraterone acetate (Primary) ; Gonadotropin releasing hormone; Prednisone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms SPARE
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Dec 2014 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
    • 20 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top